JNK signaling maintains the mesenchymal properties of multi-drug resistant human epidermoid carcinoma KB cells through snail and twist1
© Zhan et al.; licensee BioMed Central Ltd. 2013
Received: 10 December 2012
Accepted: 26 March 2013
Published: 4 April 2013
Background and methods
In addition to possess cross drug resistance characteristic, emerging evidences have shown that multiple-drug resistance (MDR) cancer cells exhibit aberrant metastatic capacity when compared to parental cells. In this study, we explored the contribution of c-Jun N-terminal kinases (JNK) signaling to the mesenchymal phenotypes and the aberrant motile capacity of MDR cells utilizing a well characterized MDR cell line KB/VCR, which is established from KB human epidermoid carcinoma cells by vincristine (VCR), and its parental cell line KB.
Taking advantage of experimental strategies including pharmacological tool and gene knockdown, we showed here that interference with JNK signaling pathway by targeting JNK1/2 or c-Jun reversed the mesenchymal properties of KB/VCR cells to epithelial phenotypes and suppressed the motile capacity of KB/VCR cells, such as migration and invasion. These observations support a critical role of JNK signaling in maintaining the mesenchymal properties of KB/VCR cells. Furthermore, we observed that JNK signaling may control the expression of both snail and twist1 in KB/VCR cells, indicating that both snail and twist1 are involved in controlling the mesenchymal characteristics of KB/VCR cells by JNK signaling.
JNK signaling is required for maintaining the mesenchymal phenotype of KB/VCR cells; and JNK signaling may maintain the mesenchymal characteristics of KB/VCR cells potentially through snail and twist1.
Keywordsc-Jun N-terminal kinases Snail Twist1 Epithelial mesenchymal transition
One of major obstacles for successful tumor chemotherapy is the development of acquired drug resistance, which possesses a property of cross drug resistance, namely multiple-drug resistance (MDR). Many efforts have been made to elucidate the mechanisms of MDR and to develop strategies for overcoming MDR aroused during chemotherapy [1, 2]. On the other hand, studies demonstrate that cancer cells survived chemotherapy acquire aberrant metastatic capacity, similar to the phenomena that cancer cells acquire MDR property after exposed to chemotherapeutic drugs [3–5]. In this regard, elucidating the molecular mechanisms underlying aberrant metastatic capacity of MDR cells is quite important, as it may provide new targets for improving the efficiency of chemotherapy.
For metastasis from a primary tumor site, cancer cells must lose cell-cell adhesion and acquire motility to invade adjacent cell layers . This process shares many similarities with epithelial-mesenchymal transition (EMT), which has been proposed as one of critical mechanisms for the acquisition of metastatic capacity by epithelial cancer cells . EMT, a highly conserved cellular program in many important phases of embryonic development, is a biological process through which epithelial cells lose their epithelial cobblestone phenotype and acquire fibroblastic and mesenchymal-like phenotypes. These dramatic phenotypic changes involve disruption of intercellular junctions, replacement of apical-basal polarity with front to back polarity, and acquisition of more potent motile ability . The hallmarks of EMT are characterized by loss of epithelial adhesion molecule E-cadherin and gain of mesenchymal markers such as N-cadherin, vimentin, et al. . A wide range of extracellular signaling pathways have been shown to trigger the process of EMT, such as signalings elicited by transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), epidermal growth factor (EGF), etc. The stimulation of these signaling pathways results in the activation of numerous transcriptional factors, including snail1 (hereafter snail), snail2/slug, twist1, ZEB1, ZEB2, hypoxia inducing factors (HIF), NF-κB, stat3, stat5 and Foxo2, thereby controlling the alterations in gene-expression patterns that underlie EMT [8, 10].
The c-Jun NH2-terminus kinases (JNKs), also called the stress-activated protein kinase (SAPK), are serine/threonine kinases that belong to the mitogen-activated protein kinase (MAPK) family. JNKs are encoded by three genes, JNK1, JNK2 and JNK3. Two of these genes, JNK1 and JNK2, are expressed ubiquitously, while JNK3 is selectively expressed in neurons. JNKs can be activated by environmental stresses, mitogens, and oncogenes, and play a critical role in tumor development [11, 12]. JNK signaling plays crucial roles in numerous biological processes such as proliferation, differentiation, survival and migration through its downstream effector activating protein1 (AP1), such as c-Jun, JunB, JunD . Much attention has been focused on the contribution of JNK signaling in MDR aroused during chemotherapy [13, 14], whereas the contribution of JNK signaling to the aberrant motile capacity of MDR cells and its underlying mechanisms remain poorly understood. This study explored the influences of JNK signaling on EMT of MDR cells to dissect the potential mechanisms underlying the aberrant motile capacity of MDR cells using a well characterized MDR cell line KB/VCR, a subline established from a human epidermoid carcinoma cell line KB by vincristine (VCR), and its parental KB cells .
Rabbit monoclonal phospho-JNK1/2 and c-Jun were purchased from Cell Signaling Technology (Beverly, MA). Rabbit monoclonal antiserum against JNK1/2, c-Jun, E-cadherin, N-cadherin, vimentin, snail, twist1, GAPDH, and β-actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA); SP600125 was purchased from Sigma (St. Louis, MO). JNK1/2 shRNA (5′-CCGGAAAGAATGTCCTACCTTCTTTCTCGAGAAAGAAGGTAGGACATTCTTTTTTTTG-3′) and shRNA control cloned into pMAGIC 7.1 lentiviral system were purchased from Sunbio (Shanghai, China). The c-Jun siRNA (5′-GCGGGAGGCAUCUUAAUUATT-3′) and control were obtained from GenePharma (Shanghai, China)
Cell lines and transfection
KB human epidermoid carcinoma cells and human epithelial kidney 293 T cells were obtained from the American Type Culture Collection (Manassas, VA) and maintained in Dulbecco’s modified Eagle’s medium (Sigma; St. Louis, MO) containing 10% fetal calf serum. The VCR-selected multiple-drug tolerant KB/VCR subline was obtained from Zhongshan University of Medical Sciences (Guangzhou, China) and routinely cultured in medium containing VCR (200 ng/ml). KB/VCR cells were cultured in VCR-free medium for at least 3–7 days prior to be used for experiments to avoid drug-associated secondary effects, and were cultured in absence of VCR for no more than 15 days to keep the MDR phenotype. The KB/VCR resistant cells were authenticated by comparing their fold resistance with that of the parental cells and examining the expression level of ABC transporters (ABCB1 and ABCG2) in KB/VCR cells cultured in the presence, or absence of VCR for about 15 days.
The c-Jun siRNA and control were transfected to KB/VCR cells using lipefectamine 2000 (Invitrogen; Carlsbad, CA) as the instructions provided by the manufacturer.
shRNA and lentivirus infections
The JNK1/2 shRNA and control were transfected to 293 T cells using lipefectamine 2000 (Invitrogen; Carlsbad, CA) as the instructions provided by the manufacturer. Viral stocks were prepared and infections performed as previously reported .
Migration and invasion assay
Migration assay and invasion assay were determined using a transwell system (Corning Costar; Acton, MA) with an 8-μm pore size membrane coated with fibronectin for migration assay or with matrigel for invasion assay as described by Li et al. . Briefly, 100 μl (5 × 104 cells) of KB or KB/VCR cells was added to the upper wells and 600 μl of DMEM with or without 10% FBS, which was used as a chemoattractant, was added to the lower wells. After incubation for 8 h at 37°C, the migrated cells or invaded cells were fixed with 90% EtOH and then stained with 0.1% crystal violet in 0.1 mol/L borate and 2% EtOH (pH 9.0). The stained cells were subsequently extracted with 10% acetic acid. The absorbance values were determined at 570 nm with a Spectrophotometer (BioTek; Winooski, VT).
Reverse transcription-PCR analyses
Total RNA was isolated with the RNAiso Plus Kit from TaKaRa (Dalian, China) as the instructions provided by the manufacturer. Total RNA was reversely transcribed using Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (TaKaRa; Dalian, China) and cDNAs were used for PCR with the following primers (Invitrogen; Shanghai, China): Snail: 5′-GAGGCGGTGGCAGACTAG-3′, 5′-GACACATCGGTCAGACCAG-3′; twist1: 5′-GGAGTCCGCAGTCTTACGAG-3′, 5′-TCTGGAGGACCTGGTAGAGG-3′; HIF-1: 5′-CAGCTATTTGCGTGTGAGGA-3′,5′-CCAAGCAGGTCATAGGTGGT-3′; NF-κB: 5′-GGCGAGCAACTCAATAAAGC-3′, 5′-GAGCAAAGGACTGCCAAGAC-3′; Foxo2: 5′-GATCACCTTGAACGGCATCT-3′, 5′-ACCTTGACGAAGCACTCGTT-3′; slug: 5′-CTTTTTCTTGCCCTCACTGC-3′, 5′-ACAGCAGCCAGATTCCTCAT-3′; ZEB1: 5′-GAGAAGCGGAAGAACGTGAC-3′, 5′-GCTTGACTTTCAGCCCTGTC-3′; ZEB2: 5′-TTCCTGGGCTACGACCATAC-3′, 5′-GCCTTGAGTGCTCGATAAGG-3′; Stat3: 5′-ACATTCTGGGCACAAACACA-3′, 5′-CACACCAGGTCCCAAGAGTT-3′; Stat5a: 5′-ACATTTGAGGAGCTGCGACT-3′, 5′-CCTCCAGAGACACCTGCTTC-3′; TATA: 5′-ACCCTTCACCAATGACTCCTATG-3′, 5′-TGACTGCAGCAAATCGCTTGG-3′. The PCR products were analyzed using agarose gel electrophoresis.
Real time-PCR analyses
Total RNA was subjected to reverse transcription with the kit from TaKaRa (Dalian, China) according to the manufacturer’s instructions. Then the cDNAs were amplified by Real-time PCR (iQ5; Bio-Rad) with the SYBR-Green kit (TaKaRa, Dalian, China) with the primers (Invitrogene; Shanghai, China) mentioned above. The alteration of mRNA expression in cells was assessed using the iQ5 optical system software by delta delta Ct method.
Cells were lysed in lysis buffer (50 mM Tris–HCl, 150 mM NaCl, 1% Nonidet P-40) supplemented with protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin and leupeptin) for 15 min on ice. Equal amounts of protein were subjected to SDS-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane (Immobilon P; Millipore). The membranes were then incubated with the appropriate antibodies as indicated.
The data of the experimental studies were expressed as the average ± s.d. Statistical differences were analyzed by the two-tailed Student’s t test and P < 0.05 was considered as significant.
KB/VCR cells exhibit mesenchymal properties and aberrant motile capacity compared to the parental cells KB
Pharmacological inhibition of JNK1/2 activation with SP600125 reverses the mesenchymal phenotypes of KB/VCR cells
Knockdown of JNK1/2 reverses the mesenchymal phenotype of KB/VCR cells
Knockdown of c-Jun disrupts the mesenchymal phenotype of KB/VCR cells
Snail and twist1 are both involved in maintaining the mesenchymal properties of KB/VCR cells by JNK signaling
In the present study, we utilized MDR cells KB/VCR , a well established MDR cell line possessing high resistance index and its parental one to examine the potential contribution of JNK signaling to EMT and aberrant motile capacity of MDR cells. By combinations of morphological, biological markers and functional analysis, we observed that KB/VCR cells possess mesenchymal properties with more potent motile capacity in comparison to KB cells, indicating that KB cells underwent EMT at the process of acquiring MDR. Furthermore, taking advantage of pharmacological tool and gene knockdown approaches, we demonstrated that JNK signaling may strictly be required for maintaining the mesenchymal properties of KB/VCR cells and its aberrant motile capacity through acting on snail and twist1, two critical transcriptional factors for EMT .
EMT, initially identified by its critical roles in developmental program of embryogenesis, has been demonstrated to be critical for numerous aspects of tumor progression, including proliferation and survival of tumor cells . Moreover, transition of epithelial cancer cells to mesenchymal ones results in alterations in adhesive properties, activation of proteolysis and enhancement of motility, thereby endowing cancer cells the ability to invade and disseminate from primary location to distal organs sites and finally promoting metastasis of cancer [7, 19]. Prior studies have shown that MDR cells acquire EMT transition compared to parental ones [20–22]. Aligned with these prior studies, our observations derived from KB/VCR and KB cells further validated this argument that cancer cells undergo EMT at the process of acquiring MDR. Thus, our data together with prior studies support that acquired mesenchymal properties may contribute, at least partially, to the aberrant motile and metastasis capacity of MDR cells arose during the process of chemotherapy.
JNK signaling has been implicated in numerous aspects of cancer progression, including the initiation, proliferation, survival and metastasis of cancers [11, 23–26], as well as the occurrence of MDR during chemotherapy . Emerging evidences have proven that JNK signaling promotes the metastasis of cancers, most likely through acting on matrix metalloproteinases [27–29], or on the small GTPases such as Rho A and Rac1 [29, 30]. Taking advantage of a constitutively active JNK plasmid, a fusion protein of JNK and its upstream activator MKK7, Wang et al. recently reported that JNK activation can promote EMT in breast cancer cells . In the current work, we observed that inhibition of JNK function via SP or knockdown of JNK expression may reverse the mesenchymal phenotypes of MDR cells KB/VCR. In addition, we further demonstrated that knockdown of c-Jun, a critical downstream transcriptional factor of JNK signaling, may disrupt the mesenchymal properties of KB/VCR cells as well. Many signaling pathways have been shown to be activated and play critical roles in maintaining the acquired chemoresistance, such as Notch and Hedgehog signaling pathways [32, 33]. Hence, it is not surprising that Notch and Hedgehog signaling may be responsible for the activation of JNK signaling in KB/VCR acquired chemoresistant cancer cells. Indeed, we observed that JNK signaling was activated by the Hedgehog in acquired chemoresistant cancer cells via a cell autonomous manner, resulting in acquisition of EMT phenotype as presented in this study and activation of the Gli transcriptional factor of Hedgehog pathway (unpublished data from our lab). In turn, Gli activation may also increase the abundances of ABCB1 and ABCG2 [33, 34]. Taken together, our data provide evidences that JNK signaling is strictly required for maintaining the mesenchymal properties of MDR cells, thus possibly involved in the aberrant metastasis capacity of MDR cells.
A variety of transcription factors including snail, slug, twist1, Zeb1 and Zeb2, to name a few, are involved in the EMT, through directly or indirectly regulating the expression of epithelial and mesenchymal markers, such as E-cadherin, N-cadherin etc. . In this study, we observed that both snail and twist1 were elevated in the MDR cells KB/VCR in comparison to its parental KB cells, indicating the involvement of both snail and twist1 in the acquisition of mesenchymal phenotypes of MDR cells. This is discrepant to the finding from others that twist1 is solely involved in the EMT of drug resistant breast cancer cells acutely selected by lethal dose of adriamycin . This discrepancy may be likely due to distinct systems used in these studies. We further found that the expression of snail and twist1 are both controlled by the JNK signaling, thus providing evidence that JNK signaling likely controls the mesenchymal phenotypes of MDR cells through acting on both snail and twist1. Our observations provide original interpretation of the molecular mechanisms for JNK signaling in regulation of EMT and in promotion of cancer metastasis.
Although great progresses have been made in the development and clinical usage of molecular target anti-cancer drugs, chemotherapy using conventional cytotoxic anti-cancer drugs is still one of efficient approaches for treatment of cancers, in despite of its limitations including MDR. Accumulating evidences have also shown that chemotherapeutic drugs usage can cause a secondary metastasis of survival cancer cells during chemotherapy and that MDR cancer cells possess aberrant metastatic capacity when compared to those sensitive to chemotherapeutic drugs [3–5]. In this regard, it is not surprising that the acquired more potent metastatic ability of MDR cells caused by traditional cytotoxic drugs usage may heavily hamper the chemotherapeutic efficacy, like MDR does. Furthermore, in addition to be involved in cancer metastasis, increasing evidences demonstrate that EMT program may also contribute to the occurrence of MDR through regulating the properties of cancer stem cell, which is significantly resistant to chemotherapy drugs [35–37]. MAPKs, such as ERK, JNK, and p38MAPK, are activated in multiple drug resistance cells . However, the role of JNK activation in acquired chemoresistance still remains controversial . Hence, this study may provide indications for interpreting the contributions of JNK signaling to MDR, through controlling the mesenchymal properties of MDR cells via acting on snail and twist1. Indeed, we observed that interfering with the expression of snail or twist1, which were both controlled by the JNK signaling as observed in this study, led to circumvent the MDR of KB/VCR cells (data to be published).
In conclusion, the finding that JNK signaling may control mesenchymal properties of MDR cells KB/VCR via snail and twist1 implicates a potential therapeutic target for improving limitations and efficacy of chemotherapy, ranging from reversal of MDR to prevention of secondly metastasis caused by chemotherapeutic drugs usage.
This work was financially supported by National Natural Science Foundation of China (81173077), the “Interdisciplinary Cooperation Team” Program for Science and Technology Innovation of the Chinese Academy of Sciences.
- Redmond KM, Wilson TR, Johnston PG, Longley DB: Resistance mechanisms to cancer chemotherapy. Front Biosci. 2008, 13: 5138-5154.View ArticlePubMedGoogle Scholar
- Lage H: An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci. 2008, 65 (20): 3145-3167. 10.1007/s00018-008-8111-5.View ArticlePubMedGoogle Scholar
- Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM: Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 2008, 68 (2): 516-520. 10.1158/0008-5472.CAN-07-3063.View ArticlePubMedGoogle Scholar
- De Larco JE, Wuertz BR, Manivel JC, Furcht LT: Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res. 2001, 61 (7): 2857-2861.PubMedGoogle Scholar
- Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, Liu BB, Li QS, Zhang W, Zhu XD, Liu L: Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer. 2010, 10: 219-10.1186/1471-2407-10-219.View ArticlePubMedPubMed CentralGoogle Scholar
- Gupta GP, Massague J: Cancer metastasis: building a framework. Cell. 2006, 127 (4): 679-695. 10.1016/j.cell.2006.11.001.View ArticlePubMedGoogle Scholar
- Yang J, Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008, 14 (6): 818-829. 10.1016/j.devcel.2008.05.009.View ArticlePubMedGoogle Scholar
- Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 2009, 119 (6): 1420-1428. 10.1172/JCI39104.View ArticlePubMedPubMed CentralGoogle Scholar
- Zeisberg M, Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009, 119 (6): 1429-1437. 10.1172/JCI36183.View ArticlePubMedPubMed CentralGoogle Scholar
- Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006, 7 (2): 131-142. 10.1038/nrm1835.View ArticlePubMedGoogle Scholar
- Wagner EF, Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009, 9 (8): 537-549. 10.1038/nrc2694.View ArticlePubMedGoogle Scholar
- Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell. 2000, 103 (2): 239-252. 10.1016/S0092-8674(00)00116-1.View ArticlePubMedGoogle Scholar
- Hayakawa J, Depatie C, Ohmichi M, Mercola D: The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem. 2003, 278 (23): 20582-20592. 10.1074/jbc.M210992200.View ArticlePubMedGoogle Scholar
- Sui H, Zhou S, Wang Y, Liu X, Zhou L, Yin P, Fan Z, Li Q: COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis. 2011, 32 (5): 667-675. 10.1093/carcin/bgr016.View ArticlePubMedGoogle Scholar
- Zhang XH, Zhang FY, Ji XJ, Li ZY: Vincristine-resistant human KB cell line and mechanism of multidrug resistance. Yao Xue Xue Bao. 1994, 29 (4): 246-251.PubMedGoogle Scholar
- Tan W, Martin D, Gutkind JS: The Galpha13-Rho signaling axis is required for SDF-1-induced migration through CXCR4. J Biol Chem. 2006, 281 (51): 39542-39549. 10.1074/jbc.M609062200.View ArticlePubMedGoogle Scholar
- Li MH, Miao ZH, Tan WF, Yue JM, Zhang C, Lin LP, Zhang XW, Ding J: Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin Cancer Res. 2004, 10 (24): 8266-8274. 10.1158/1078-0432.CCR-04-0951.View ArticlePubMedGoogle Scholar
- Bennett BL, Sasaki DT, Murray BW, O’Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A. 2001, 98 (24): 13681-13686. 10.1073/pnas.251194298.View ArticlePubMedPubMed CentralGoogle Scholar
- Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139 (5): 871-890. 10.1016/j.cell.2009.11.007.View ArticlePubMedGoogle Scholar
- Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP, Xu ZD: Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 2009, 15 (8): 2657-2665. 10.1158/1078-0432.CCR-08-2372.View ArticlePubMedGoogle Scholar
- Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69 (6): 2400-2407. 10.1158/0008-5472.CAN-08-4312.View ArticlePubMedPubMed CentralGoogle Scholar
- Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009, 106 (33): 13820-13825. 10.1073/pnas.0905718106.View ArticlePubMedPubMed CentralGoogle Scholar
- Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S: c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood. 2005, 106 (4): 1382-1391. 10.1182/blood-2004-10-3819.View ArticlePubMedPubMed CentralGoogle Scholar
- Das M, Garlick DS, Greiner DL, Davis RJ: The role of JNK in the development of hepatocellular carcinoma. Genes Dev. 2011, 25 (6): 634-645. 10.1101/gad.1989311.View ArticlePubMedPubMed CentralGoogle Scholar
- Sancho R, Nateri AS, de Vinuesa AG, Aguilera C, Nye E, Spencer-Dene B, Behrens A: JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J. 2009, 28 (13): 1843-1854. 10.1038/emboj.2009.153.View ArticlePubMedPubMed CentralGoogle Scholar
- Fujishita T, Aoki M, Taketo MM: JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(Delta716) mice. Gastroenterology. 2011, 140 (5): 1556-1563. 10.1053/j.gastro.2011.02.007. e1556View ArticlePubMedGoogle Scholar
- Cheung LW, Leung PC, Wong AS: Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res. 2006, 66 (22): 10902-10910. 10.1158/0008-5472.CAN-06-2217.View ArticlePubMedGoogle Scholar
- McMurtry V, Simeone AM, Nieves-Alicea R, Tari AM: Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells. Clin Exp Metastasis. 2009, 26 (3): 197-204. 10.1007/s10585-008-9231-x.View ArticlePubMedGoogle Scholar
- Fromigue O, Hamidouche Z, Marie PJ: Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem. 2008, 283 (45): 30549-30556. 10.1074/jbc.M801436200.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang Y, Rivera Rosado LA, Moon SY, Zhang B: Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling. J Biol Chem. 2009, 284 (19): 12956-12965. 10.1074/jbc.M807845200.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang J, Kuiatse I, Lee AV, Pan J, Giuliano A, Cui X: Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer Res. 2010, 8 (2): 266-277. 10.1158/1541-7786.MCR-09-0221.View ArticlePubMedPubMed CentralGoogle Scholar
- Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB, Schwartz GK: Gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009, 69 (2): 573-582. 10.1158/0008-5472.CAN-08-2088.View ArticlePubMedPubMed CentralGoogle Scholar
- Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP, Spek CA: Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene. 2010, 29 (48): 6314-6322. 10.1038/onc.2010.375.View ArticlePubMedGoogle Scholar
- Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, Vega F: ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene. 2011, 30 (49): 4874-4886. 10.1038/onc.2011.195.View ArticlePubMedPubMed CentralGoogle Scholar
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133 (4): 704-715. 10.1016/j.cell.2008.03.027.View ArticlePubMedPubMed CentralGoogle Scholar
- Singh A, Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010, 29 (34): 4741-4751. 10.1038/onc.2010.215.View ArticlePubMedPubMed CentralGoogle Scholar
- Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 2005, 5 (4): 275-284. 10.1038/nrc1590.View ArticlePubMedGoogle Scholar
- Sui H, Fan ZZ, Li Q: Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 2012, 40 (2): 426-435.View ArticlePubMedGoogle Scholar
- Vasilevskaya I, O’Dwyer PJ: Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Updat. 2003, 6 (3): 147-156. 10.1016/S1368-7646(03)00043-8.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/180/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.